Avenue Therapeutics is a biotechnology business based in the US. Avenue Therapeutics shares (ATXI) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $2.03 – an increase of 2.79% over the previous week. Avenue Therapeutics employs 3 staff and has a market cap (total outstanding shares value) of 0.00.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $2.03 |
|---|---|
| 52-week range | $1.90 - $45.75 |
| 50-day moving average | $2.59 |
| 200-day moving average | $6.78 |
| Wall St. target price | $12.00 |
| PE ratio | 0.0526 |
| Dividend yield | N/A |
| Earnings per share (TTM) | $37.48 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.025 from 2024-10-14
| 1 week (2024-10-08) | 2.79% |
|---|---|
| 1 month (2024-09-13) | -27.94% |
| 3 months (2024-07-15) | -41.98% |
| 6 months (2024-04-15) | 1,520.00% |
| 1 year (2023-10-13) | 237.50% |
|---|---|
| 2 years (2022-10-14) | -39.19% |
| 3 years (2021-10-13) | 55.77% |
| 5 years (2019-10-15) | 5.3 |
Valuing Avenue Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Avenue Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Avenue Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 0x. In other words, Avenue Therapeutics shares trade at around 0x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -201.35% |
| Return on equity TTM | -535.1% |
| Profit margin | 0% |
| Book value | $4.00 |
| Market Capitalization | $2.8 million |
TTM: trailing 12 months
We're not expecting Avenue Therapeutics to pay a dividend over the next 12 months.
Avenue Therapeutics's shares were split on a 1:75 basis on 25 April 2024. So if you had owned 75 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Avenue Therapeutics shares – just the quantity. However, indirectly, the new 7400% higher share price could have impacted the market appetite for Avenue Therapeutics shares which in turn could have impacted Avenue Therapeutics's share price.
Over the last 12 months, Avenue Therapeutics's shares have ranged in value from as little as $1.9 up to $45.75. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Avenue Therapeutics's is -0.175. This would suggest that Avenue Therapeutics's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Avenue Therapeutics has bucked the trend.
Avenue Therapeutics, Inc. , a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida. .
Fundamental analysis of stocks can help you become a better investor and find the true value of stocks and other assets.
These are the stocks to buy when you don’t have much to spend.
Explore the best bonuses for opening a new brokerage account.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
eToro is a robust trading platform with an easy-to-use interface and no commissions on stocks and ETFs.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out the best-performing ETFs so far in 2024.
Read our beginner’s guide to trading options in the US.